Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODICON 28 vs EMOQUETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces changes in cervical mucus and endometrium, impeding sperm penetration and implantation.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Prevention of pregnancy
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD),Panic disorder,Premenstrual dysphoric disorder (PMDD),Post-traumatic stress disorder (PTSD)
One tablet orally once daily, each tablet containing 0.035 mg ethinyl estradiol and 0.4 mg norethindrone, taken at the same time each day for 21 days followed by 7 days of placebo tablets.
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
Terminal elimination half-life: 13-19 hours (mean 16 hours) for norethindrone; steady state achieved within 5-7 days.
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Ethinyl estradiol undergoes hepatic metabolism via CYP3A4; norethindrone is metabolized primarily via reduction and conjugation, with involvement of CYP3A4.
EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette.
Renal: 50-60% as metabolites, fecal: 40-50% as metabolites, with enterohepatic circulation; less than 1% unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Norethindrone: 61-67% bound to SHBG and albumin (55% to SHBG, 45% to albumin); ethinyl estradiol: 97-98% bound to albumin, not bound to SHBG.
Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein.
Norethindrone: Vd approximately 4 L/kg (range 2-6 L/kg), indicating extensive tissue distribution; ethinyl estradiol: Vd approximately 2-4 L/kg.
Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments.
Oral norethindrone: 45-65% due to first-pass metabolism; ethinyl estradiol: 38-48% oral bioavailability.
Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); consider alternative contraception due to potential hormonal accumulation.
GFR 30-89 m L/min: no adjustment needed. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: use with caution; maximum dose 1 mg per day.
Contraindicated in acute hepatic disease or severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment (Child-Pugh A or B); monitor liver function; consider alternative contraception.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended.
Not indicated for use before menarche. For post-menarche adolescents: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day.
Not indicated for use in postmenopausal women. Efficacy for contraception not applicable; no dosing recommendations for this population.
Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity, especially in women over 35. Women should be strongly advised not to smoke.
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, cerebrovascular disease, myocardial infarction),Hepatic disease (jaundice, hepatic adenomas),Hypertension,Gallbladder disease,Carbohydrate and lipid effects,Ocular lesions (e.g., retinal thrombosis),Headache (including migraine),Menstrual irregularities/breakthrough bleeding,Depression,Reduced efficacy with enzyme-inducing drugs,Bone mineral density changes,Hereditary angioedema
Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles.
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular disease,Coronary artery disease,Known or suspected carcinoma of the breast,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenomas or carcinomas,Known or suspected liver disease,Heavy smoking (≥15 cigarettes/day) and age ≥35,Hypersensitivity to any component
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (Cr Cl < 15 m L/min)
Grapefruit and grapefruit juice may increase ethinyl estradiol levels by inhibiting CYP3A4, but the effect is variable; advise caution or avoid concurrent intake. No other significant food interactions are known. High-fat meals may delay absorption but do not reduce overall efficacy.
No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy.
FDA Pregnancy Category X. First trimester: increased risk of neural tube defects, congenital heart defects, and other malformations due to estrogen/progestin exposure. Second and third trimesters: associated with elevated risks of preterm birth, low birth weight, and neonatal complications. Use contraindicated in pregnancy.
EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy.
Safety: Small amounts of ethinyl estradiol and progestin (norethindrone) are excreted in breast milk. M/P ratio: Not established for this specific combination; ethinyl estradiol M/P ~0.2-0.4. May reduce milk production and alter milk composition. Not recommended during breastfeeding; alternative contraception advised.
EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose.
No dose adjustment required as drug is contraindicated in pregnancy. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) are not relevant due to contraindication. If inadvertent exposure occurs, discontinue drug.
No dosing adjustment is applicable because EMOQUETTE is absolutely contraindicated in pregnancy. If exposure occurs, immediate discontinuation is required.
MODICON 28 is a combined oral contraceptive containing ethinyl estradiol 0.035 mg and norethindrone 0.5 mg. It is crucial to counsel patients on the importance of taking the pill at the same time daily to maintain consistent hormone levels. The regimen includes 21 active pills followed by 7 placebo pills; during the placebo week, withdrawal bleeding typically occurs. For missed pills: if one pill is missed, take it as soon as remembered and continue schedule; if two or more are missed, take the most recent missed pill and use backup contraception for 7 days. Consider potential drug interactions with antibiotics, anticonvulsants (e.g., carbamazepine, phenytoin), and St. John's wort, which may reduce contraceptive efficacy. Smoking increases risk of serious cardiovascular events, especially in women over 35. Monitor blood pressure at baseline and periodically. Caution in patients with history of thromboembolic disorders, migraine with aura, hypertension, or liver disease.
EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels.
Take one pill daily at the same time, preferably after an evening meal or at bedtime to minimize nausea.,The pack contains 21 active (hormone) pills and 7 placebo (reminder) pills; withdrawal bleeding usually occurs during the placebo week.,If you miss a pill, refer to the package insert instructions; use backup contraception (e.g., condoms) if needed.,Use additional non-hormonal contraception during the first 7 days of starting the pill if switching from another method.,Seek immediate medical attention if you experience symptoms of a blood clot, such as sudden leg pain or swelling, chest pain, shortness of breath, or severe headache.,This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Inform your healthcare provider of all medications and supplements you take, especially antibiotics, anticonvulsants, and St. John's wort.,Avoid smoking, especially if over 35, as it increases the risk of serious side effects.
Take one tablet at the same time every day, with or without food.,If you miss a dose, take it as soon as you remember and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in first few months.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODICON 28 vs EMOQUETTE, answered by our medical review team.
MODICON 28 is a Combination Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces changes in cervical mucus and endometrium, impeding sperm penetration and implantation.. EMOQUETTE is a Combination Oral Contraceptive that works by EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODICON 28 and EMOQUETTE depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODICON 28 is: One tablet orally once daily, each tablet containing 0.035 mg ethinyl estradiol and 0.4 mg norethindrone, taken at the same time each day for 21 days followed by 7 days of placebo tablets.. The standard adult dose of EMOQUETTE is: 0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODICON 28 and EMOQUETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODICON 28 is classified as Category C. FDA Pregnancy Category X. First trimester: increased risk of neural tube defects, congenital heart defects, and other malformations due to estrogen/progestin exposure. Second and t. EMOQUETTE is classified as Category C. EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.